市場調查報告書
商品編碼
1464799
管腔成形術市場:依手術技術、應用分類 - 2024-2030 年全球預測Canaloplasty Market by Surgical Technique (Ab-Externo Canaloplasty, Ab-Interno Canaloplasty), Application (Academy & Research Laboratory, Ambulatory Surgical Centers, Hospitals & Ophthalmology Clinics) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
管腔成形術市場規模預計2023年為5.1726億美元,2024年達到5.5404億美元,預計2030年將達到8.4515億美元,複合年成長率為7.26%。
淚管成形術是一種用於治療青光眼的醫療手術。青光眼是一種由眼內壓升高引起的慢性眼部疾病,導致視神經損傷並最終喪失視力。與更具侵入性的手術方法不同,眼管成形術使用微導管來拓寬眼睛的自然引流通道,使房水(有助於維持眼內壓的液體)的流出更容易進行。這種方法是傳統手術的一種較不侵入性的替代方法,旨在降低眼內壓,同時最大限度地減少與侵入性手術相關的風險。由於全球青光眼盛行率不斷上升以及對微創手術解決方案的需求不斷成長,管道成形術市場正在經歷顯著成長。人口老化、對青光眼的認知不斷提高以及醫療技術的進步正在進一步推動市場向前發展。然而,市場面臨著手術成本高昂以及患者和醫生更容易獲得的替代治療方法(例如藥物和其他外科手術)的可用性等挑戰。旨在提高微創手術療效和安全性的研究和開發正在進行中,加上醫療保健基礎設施的成長和患者對微創手術的偏好不斷增加,為預期的市場擴張提供了肥沃的土壤。此外,提高血管成形術的可負擔性和可及性的努力可能會為青光眼治療領域的相關人員帶來光明的前景,並增加其採用率。
主要市場統計 | |
---|---|
基準年[2023] | 51726萬美元 |
預測年份 [2024] | 55404萬美元 |
預測年份 [2030] | 8.4515億美元 |
複合年成長率(%) | 7.26% |
手術技術:Abextanol 腔成形術技術因其微創性質而越來越受歡迎
Abextanocanaloplasty 是一種手術,外科醫生在眼部組織上做一個小切口以進入施累姆管,施累姆管是眼睛引流系統的重要組成部分。一旦進入,將微導管插入管中以促進液體排放。外科醫生還可以注射凝膠狀物質以保持管子打開。這種方法作為一種比傳統青光眼手術侵入性較小的選擇而受到關注,因為它可以在不完全切除眼組織的情況下顯著降低眼內壓。相比之下,眼球內腔成形術是在眼球內部進行的。這是一種利用角膜上的微小切口直接進入施累姆氏管的新方法。與 abextano 手術類似,使用微導管和特殊器械來擴張管腔並允許液體排放,但不進行外部切口。這種方法通常是首選,因為它侵入性較小,恢復時間較快,並且可以與其他微創青光眼手術 (MIGS) 結合使用,以提供更好的壓力控制。
應用:管腔成形術在醫院和眼科診所的新應用
在學術團體和研究機構中,管道成形術是一個研究主題,而不是直接應用於患者的治療方法。當務之急是研究淚管成形術治療青光眼的有效性、安全性和改善潛力。研究實驗室和學術機構經常進行臨床試驗,分析結果,並將淚管成形術與其他青光眼治療方法進行比較。這些環境旨在加深理解、完善技術並為有關這種微創手術的知識做出貢獻。門診手術中心 (ASC) 提供了一個患者無需住院即可接受手術的環境。使用 ASC 進行管道成形術強調了此手術的微創性,強調患者的便利性、成本節約和效率。醫院和眼科診所是接受管道成形術患者的主要治療中心。這些設施擁有必要的基礎設施和專業人員來執行這種精細的眼科手術。眼科診所通常是大型醫院系統的一部分或附屬機構,並且擁有眼科護理方面的專業知識,包括我們提供擅長管道成形術的眼科醫生。
區域洞察
在美洲,對眼管成形術的需求主要是由更容易患青光眼的老齡化人口以及有利於獲得先進眼科護理的成熟醫療基礎設施所推動的。該地區擁有活躍的法規環境,美國食品藥物管理局(FDA) 等監管機構制定了嚴格的指導方針,以確保管道成形術設備和手術的安全性和有效性。在亞太地區 (APAC),經濟的快速成長、醫療保健標準的提高以及醫療成本的上升正在刺激包括管道成形術在內的先進醫療方法的普及。該地區龐大的患者群體和人們對青光眼治療選擇的認知不斷提高,導致對這種治療方法的需求不斷成長。歐洲、中東和非洲地區的管道成形術呈現出多樣化的格局,在歐洲藥品管理局 (EMA) 等強大監管機構的支持下,該技術的採用不斷增加。這些組織確保管腔成形術設備符合高安全性和性能標準。同時,由於醫療基礎設施投資增加以及對先進青光眼管理解決方案需求的日益認知,中東和非洲正在經歷逐步成長。儘管存在這些不同的趨勢,但在不斷發展的監管標準和日益重視以患者為中心的護理的推動下,歐洲、中東和非洲地區的總體趨勢包括我們正在逐漸接受微創手術。
FPNV定位矩陣
FPNV定位矩陣對於評估管道成形術市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對管腔成形術市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.管腔成形術市場的市場規模與預測是多少?
2.在Luminoplasty市場預測期間內需要考慮投資的產品、細分市場、應用和領域有哪些?
3.管腔成形術市場的技術趨勢和法規結構是什麼?
4.Luminoplasty市場主要供應商的市場佔有率是多少?
5.進入管道成形術市場的合適型態和策略手段是什麼?
[191 Pages Report] The Canaloplasty Market size was estimated at USD 517.26 million in 2023 and expected to reach USD 554.04 million in 2024, at a CAGR 7.26% to reach USD 845.15 million by 2030.
Canaloplasty is a medical procedure employed in treating glaucoma, a chronic condition of the eye due to increased intraocular pressure that can lead to optic nerve damage and, ultimately, loss of vision. Unlike more invasive surgical options, canaloplasty utilizes a microcatheter to enlarge the eye's natural drainage canal, facilitating a more manageable outflow of aqueous humor, the fluid responsible for maintaining eye pressure. This method presents a less aggressive alternative to traditional surgeries, aiming to reduce intraocular pressure while minimizing the risks associated with more invasive interventions. The canaloplasty market has witnessed significant growth, driven by the rising prevalence of glaucoma worldwide and the increasing need for less invasive surgical solutions. Aging populations, heightened awareness of glaucoma, and advancements in medical technology have further propelled the market forward. However, the market faces challenges, including the high cost of the procedure and the availability of alternative treatment options, including medication or other surgical procedures that may be more familiar to patients and practitioners. Furthermore, ongoing research and development aimed at enhancing the efficacy and safety of the method, coupled with growing healthcare infrastructure and increasing patient selection for minimally invasive surgeries, are expected to offer fertile ground for market expansion. Moreover, efforts to enhance the affordability and accessibility of canaloplasty can potentially increase its adoption, presenting a promising outlook for stakeholders in the glaucoma treatment landscape.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 517.26 million |
Estimated Year [2024] | USD 554.04 million |
Forecast Year [2030] | USD 845.15 million |
CAGR (%) | 7.26% |
Surgical Technique: Growing preference for the ab-interno canaloplasty technique for its minimally invasive nature
Ab-externo canaloplasty is where the surgeon creates a small incision in the eye tissue to access the schlemm's canal, a crucial component of the eye's drainage system. Once accessed, a microcatheter is inserted into the canal to enlarge and facilitate better fluid drainage. The surgeon may also inject a gel-like material to keep the canal open. This method is notable for significantly reducing intraocular pressure without requiring a complete removal of eye tissue, offering a less invasive option than traditional glaucoma surgeries. The ab-interno canaloplasty technique, in contrast, is performed from inside the eye. It is a newer approach involving a microscopic incision through the cornea to directly access the schlemm's canal. Similar to the ab-externo method, a microcatheter or a specialized device is used to dilate the canal and facilitate fluid drainage, whereas it is done without creating an external incision. This procedure is often preferred for its minimally invasive nature, reduced recovery times, and because it can be performed with other minimally invasive glaucoma surgeries (MIGS) to achieve better pressure control.
Application: Emerging applications of canaloplasty in hospitals and ophthalmology clinics
In academic and research laboratories, canaloplasty is a subject of study rather than a treatment applied directly to patients. These settings prioritize investigating the efficacy, safety, and potential improvements of canaloplasty as a treatment for glaucoma. Research labs and academic institutions often conduct clinical trials, analyze outcomes, and compare canaloplasty to other glaucoma treatments. These environments aim to advance understanding, refine techniques, and contribute to the knowledge surrounding this minimally invasive procedure. Ambulatory surgical centers (ASCs) offer a setting where patients can undergo this procedure without needing hospital admission. Using ASCs for canaloplasty underscores the procedure's minimally invasive nature, emphasizing patient convenience, reduced costs, and efficiency. Hospitals and ophthalmology clinics serve as primary points of care for patients undergoing canaloplasty. These institutions have the necessary infrastructure and specialized personnel to perform this delicate eye surgery. Ophthalmology clinics, often part of or affiliated with larger hospital systems, provide focused expertise in eye health, including access to ophthalmologists skilled in canaloplasty.
Regional Insights
In the Americas, the need for canaloplasty procedures is chiefly driven by an aging population vulnerable to glaucoma and an established healthcare infrastructure that facilitates access to advanced ophthalmic treatments. The region benefits from a proactive regulatory environment, with agencies, including the U.S. Food and Drug Administration (FDA), setting stringent guidelines that ensure the safety and efficacy of canaloplasty devices and procedures. In the Asia-Pacific (APAC) region, rapid economic growth, improved healthcare standards, and increased healthcare spending have catalyzed the adoption of advanced medical treatments, including canaloplasty. The region's vast patient pool and growing awareness about glaucoma management options contribute to the procedure's growing need. The EMEA region presents a diverse landscape for canaloplasty, with increasing technology adoption underpinned by strong regulatory bodies inlcuding the European Medicines Agency (EMA). These agencies ensure that canaloplasty devices meet high safety and performance standards. In contrast, the Middle East and Africa are gradually growing, driven by increasing investments in healthcare infrastructure and a growing recognition of the need for advanced glaucoma management solutions. Despite the diversity, the overarching trend in EMEA is towards embracing minimally invasive procedures like canaloplasty, facilitated by evolving regulatory standards and an increasing emphasis on patient-centered care.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Canaloplasty Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Canaloplasty Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Canaloplasty Market, highlighting leading vendors and their innovative profiles. These include Carl Zeiss Meditec AG, Ellex Medical Pty Ltd., Glaukos Corporation, iSTAR Medical, Nova Eye Medical Limited, Qura, Inc., and Sight Sciences, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Canaloplasty Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Canaloplasty Market?
3. What are the technology trends and regulatory frameworks in the Canaloplasty Market?
4. What is the market share of the leading vendors in the Canaloplasty Market?
5. Which modes and strategic moves are suitable for entering the Canaloplasty Market?